HU0001547D0 - - Google Patents

Info

Publication number
HU0001547D0
HU0001547D0 HU0001547A HUP0001547A HU0001547D0 HU 0001547 D0 HU0001547 D0 HU 0001547D0 HU 0001547 A HU0001547 A HU 0001547A HU P0001547 A HUP0001547 A HU P0001547A HU 0001547 D0 HU0001547 D0 HU 0001547D0
Authority
HU
Hungary
Application number
HU0001547A
Other languages
Hungarian (hu)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU0001547(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of HUP0001547A2 publication Critical patent/HUP0001547A2/hu
Publication of HU0001547D0 publication Critical patent/HU0001547D0/hu
Publication of HUP0001547A3 publication Critical patent/HUP0001547A3/hu
Publication of HU227589B1 publication Critical patent/HU227589B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0001547A 1996-12-20 1997-12-16 Crystal form of (s)-omeprazole HU227589B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604793A SE510666C2 (sv) 1996-12-20 1996-12-20 Nya Kristallmodifikationer
PCT/SE1997/002125 WO1998028294A1 (en) 1996-12-20 1997-12-16 A novel compound form

Publications (4)

Publication Number Publication Date
HUP0001547A2 HUP0001547A2 (hu) 2002-05-29
HU0001547D0 true HU0001547D0 (enExample) 2002-05-29
HUP0001547A3 HUP0001547A3 (en) 2002-06-28
HU227589B1 HU227589B1 (en) 2011-09-28

Family

ID=20405146

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001547A HU227589B1 (en) 1996-12-20 1997-12-16 Crystal form of (s)-omeprazole

Country Status (36)

Country Link
US (1) US6162816A (enExample)
EP (1) EP0946547B1 (enExample)
JP (1) JP4402174B2 (enExample)
KR (1) KR20000069595A (enExample)
CN (1) CN1109684C (enExample)
AR (1) AR010361A1 (enExample)
AT (1) ATE236898T1 (enExample)
AU (1) AU730129B2 (enExample)
BR (1) BR9714059A (enExample)
CA (1) CA2274076C (enExample)
CZ (1) CZ294784B6 (enExample)
DE (1) DE69720774T2 (enExample)
DK (1) DK0946547T3 (enExample)
EE (1) EE03923B1 (enExample)
EG (1) EG24414A (enExample)
ES (1) ES2194231T3 (enExample)
HU (1) HU227589B1 (enExample)
ID (1) ID21850A (enExample)
IL (1) IL130450A0 (enExample)
IS (1) IS1981B (enExample)
MY (1) MY117032A (enExample)
NO (1) NO317191B1 (enExample)
NZ (1) NZ336024A (enExample)
PL (1) PL190377B1 (enExample)
PT (1) PT946547E (enExample)
RS (1) RS49685B (enExample)
RU (1) RU2184734C2 (enExample)
SA (1) SA97180739B1 (enExample)
SE (1) SE510666C2 (enExample)
SI (1) SI0946547T1 (enExample)
SK (1) SK285151B6 (enExample)
TR (1) TR199901410T2 (enExample)
TW (1) TW538039B (enExample)
UA (1) UA55436C2 (enExample)
WO (1) WO1998028294A1 (enExample)
ZA (1) ZA9711046B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
JP2000344739A (ja) * 1999-06-01 2000-12-12 Sumitomo Chem Co Ltd Ｎ−保護−アゼチジン−２−カルボン酸の製造方法
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CN100562318C (zh) * 2000-05-15 2009-11-25 武田药品工业株式会社 晶体的制备方法
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
AU2001276721A1 (en) 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
SI20875A (sl) 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
IL159129A0 (en) 2001-06-01 2004-05-12 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
GB2376231A (en) 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CA2491118A1 (en) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
US7169793B2 (en) 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
WO2004020436A1 (en) * 2002-08-30 2004-03-11 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
US20040235903A1 (en) * 2002-10-22 2004-11-25 Khanna Mahavir Singh Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
MXPA05009183A (es) * 2003-02-28 2005-10-20 Ranbaxy Lab Ltd Polimorfos de s-omeprazol.
JP4787017B2 (ja) * 2003-03-24 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体またはその塩のアモルファスの製造方法
CN1842525A (zh) * 2003-05-05 2006-10-04 兰贝克赛实验室有限公司 苯并咪唑衍生物的钡盐
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US8658799B2 (en) * 2004-06-24 2014-02-25 Astrazeneca Ab Process for the preparation of crystalline modifications for use in the preparation of esomeperazole sodium salt
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20090298884A1 (en) * 2005-05-06 2009-12-03 Glenmark Generics Ltd. Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
US8247566B2 (en) * 2005-06-08 2012-08-21 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
US7563812B2 (en) 2005-06-15 2009-07-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
NL2000126C2 (nl) * 2005-07-15 2008-01-29 Solvay Werkwijze voor de vervaardiging van eptifibatide.
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
WO2007054951A1 (en) * 2005-11-14 2007-05-18 Hetero Drugs Limited Process for amorphous esomeprazole
BRPI0619158A2 (pt) * 2005-12-05 2011-09-20 Astrazeneca Ab processo para preparar forma que não que não seja sal de esomeprazol, composto, formulação farmacêutica, e, método de tratamento
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
SI1973896T1 (sl) 2005-12-28 2009-08-31 Union Quimico Farma Postopek priprave (S) - enantiomere omeprazola
EP2000468A1 (en) * 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2009047775A2 (en) * 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphs of esomeprazole salts
NZ588379A (en) 2008-03-10 2012-07-27 Takeda Pharmaceutical Crystal of benzimidazole compound
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EP2510089B1 (en) 2009-12-08 2015-10-21 Codexis, Inc. Synthesis of prazole compounds
HUE037616T2 (hu) 2010-12-08 2018-09-28 Codexis Inc Biokatalizátorok és eljárások armodafinil szintéziséhez
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
RU2501549C1 (ru) 2012-08-30 2013-12-20 Авва Девелопмент Лтд Фармацевтическая композиция для лечения гастроэзофагеальной рефлюксной болезни
CN107043367A (zh) * 2017-05-26 2017-08-15 重庆莱美隆宇药业有限公司 一种中性s‑奥美拉唑的干燥工艺
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i

Also Published As

Publication number Publication date
CN1241183A (zh) 2000-01-12
EE9900259A (et) 2000-02-15
PL334297A1 (en) 2000-02-14
RS49685B (sr) 2007-11-15
IS1981B (is) 2005-01-14
ES2194231T3 (es) 2003-11-16
IL130450A0 (en) 2000-06-01
PL190377B1 (pl) 2005-12-30
EE03923B1 (et) 2002-12-16
DK0946547T3 (da) 2003-06-30
ID21850A (id) 1999-08-05
ATE236898T1 (de) 2003-04-15
CN1109684C (zh) 2003-05-28
AU5502698A (en) 1998-07-17
MY117032A (en) 2004-04-30
HUP0001547A3 (en) 2002-06-28
YU28199A (sh) 2002-03-18
NZ336024A (en) 2001-02-23
WO1998028294A1 (en) 1998-07-02
SA97180739B1 (ar) 2006-05-20
AR010361A1 (es) 2000-06-07
HK1022909A1 (en) 2000-08-25
RU2184734C2 (ru) 2002-07-10
CZ294784B6 (cs) 2005-03-16
CA2274076C (en) 2008-09-30
HU227589B1 (en) 2011-09-28
JP2001507025A (ja) 2001-05-29
ZA9711046B (en) 1998-06-22
CA2274076A1 (en) 1998-07-02
BR9714059A (pt) 2000-05-09
NO993068L (no) 1999-06-21
SE9604793D0 (sv) 1996-12-20
NO993068D0 (no) 1999-06-21
AU730129B2 (en) 2001-02-22
DE69720774D1 (de) 2003-05-15
KR20000069595A (ko) 2000-11-25
IS5070A (is) 1999-06-07
SE510666C2 (sv) 1999-06-14
SK285151B6 (sk) 2006-07-07
HUP0001547A2 (hu) 2002-05-29
CZ220299A3 (cs) 2000-02-16
UA55436C2 (uk) 2003-04-15
EP0946547B1 (en) 2003-04-09
SK76599A3 (en) 1999-12-10
NO317191B1 (no) 2004-09-13
TW538039B (en) 2003-06-21
EG24414A (en) 2009-05-25
US6162816A (en) 2000-12-19
SE9604793L (sv) 1998-06-21
TR199901410T2 (xx) 1999-08-23
SI0946547T1 (en) 2003-10-31
PT946547E (pt) 2003-07-31
JP4402174B2 (ja) 2010-01-20
DE69720774T2 (de) 2004-02-05
EP0946547A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
AR026661A2 (enExample)
BRPI9713914B8 (enExample)
ITMI960068A0 (enExample)
BR7600721U (enExample)
BR7601346U (enExample)
BR9603859A (enExample)
ITMI960315A0 (enExample)
CN3041115S (enExample)
CN3039060S (enExample)
CN3039213S (enExample)
CN3040024S (enExample)
CN3040367S (enExample)
CN3040543S (enExample)
CN3040550S (enExample)
CN3040805S (enExample)
CN3041207S (enExample)
CN3041374S (enExample)
CN3041383S (enExample)
CN3042193S (enExample)
CN3042289S (enExample)
CN3042424S (enExample)
CN3042589S (enExample)
CN3043305S (enExample)
CN3043413S (enExample)
CN3043414S (enExample)

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees